AstraZeneca-partnered Pinetree nears $47M Series B for protein degradersnews2025-10-23T11:00:54+00:00October 23rd, 2025|Endpoints News|
Tahoe Therapeutics releases virtual cell AI modelnews2025-10-23T11:00:43+00:00October 23rd, 2025|Endpoints News|
Roche in talks with US on drug pricing, sets out pipeline and dealmaking ambitionsnews2025-10-23T10:34:49+00:00October 23rd, 2025|Endpoints News|
Moderna’s CMV vaccine fails Phase 3 study, company to halt most developmentnews2025-10-22T20:05:30+00:00October 22nd, 2025|Endpoints News|
Alkermes to buy Avadel for up to $2.1Bnews2025-10-22T19:27:45+00:00October 22nd, 2025|Endpoints News|
Major pharma companies spent more on lobbying in third quarternews2025-10-22T19:14:28+00:00October 22nd, 2025|Endpoints News|
Amy Gleason, a top Trump health official, calls for more access to patient datanews2025-10-22T18:59:33+00:00October 22nd, 2025|Endpoints News|
Arcturus announces mixed results of mRNA cystic fibrosis therapy, Covid-19 vaccine delaynews2025-10-22T18:39:22+00:00October 22nd, 2025|Endpoints News|
Thermo Fisher, Danaher stand to gain from drugmakers’ onshoring effortsnews2025-10-22T17:11:30+00:00October 22nd, 2025|Endpoints News|
A trio of biotechs target $250M offerings; Regeneron stops cell therapy trialnews2025-10-22T15:08:19+00:00October 22nd, 2025|Endpoints News|
